Oncopeptides’ Pepaxti Gains EMA Nod, Driving Share Surge and Oncology Breakthroughs
Oncopeptides’ new EMA approval for Pepaxti lifts it to third‑line therapy, boosting shares and expanding its cancer‑treatment pipeline.
2 minutes to read
ONCOPEPTIDES